Results 131 to 140 of about 577,051 (308)
Pragmatic Ayurveda approach towards End-stage renal disease
Chronic Kidney Disease (CKD) has different pathophysiologic processes associated with progressive kidney failure and decreased Glomerular Filtration Rate (GFR). End-stage Renal Disease (ESRD) is defined as a GFR of
N. Rahul +3 more
doaj +1 more source
LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li +12 more
wiley +1 more source
Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong +5 more
wiley +1 more source
DOT1L as a central epigenetic regulator of EndoMT and pulmonary fibrosis. Acting as an early epigenetic switch, it translates TGFβ–SMAD signaling into H3K79me2‐mediated chromatin remodeling, selectively activates fibrosis‐related genes, and primes ECs for rapid mesenchymal transition.
Yaofeng Wang +11 more
wiley +1 more source
This study generates high‐fidelity synthetic longitudinal records for a million‐patient diabetes cohort, successfully replicating clinical predictive performance. However, deeper analysis reveals algorithmic biases and trajectory inconsistencies that escape standard quality metrics. These findings challenge current validation norms, demonstrating why a
Francisco Ortuño +5 more
wiley +1 more source
β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma
β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto +20 more
wiley +1 more source
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li +6 more
wiley +1 more source
In a randomized clinical trial, we test the potential of combined nicotinamide (NAM) and pyridoxine (PN) to improve muscle recovery through muscle stem cell (MuSC) activity. Daily oral NAM and PN supplementation after high intensity muscle contractions enhances MuSC activation and differentiation, and accelerates muscle regeneration, providing new ...
Grith Højfeldt +14 more
wiley +1 more source
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey +6 more
wiley +1 more source
The versatile CaO2@CuMOF@HAP nanohybrid demonstrates an outstanding MMP9/pH‐triggered release performance for sequential release of osteogenic growth peptide into deep‐seated tumor‐infiltrated bone destruction areas and dual ions into tumor cells, enabling efficient tumor‐associated osteolysis restoration and tumor elimination for more comprehensive ...
Lan Liu +8 more
wiley +1 more source

